CG Oncology, Inc. 8-K

What Happened
CG Oncology, Inc. announced its quarterly earnings and financial results for the quarter ended March 31, 2026 by issuing a press release on May 8, 2026. The company filed a Current Report on Form 8‑K (Item 2.02) to disclose the results; the press release is attached as Exhibit 99.1 and is incorporated by reference.

Key Details

• The press release reporting the quarterly results was issued on May 8, 2026 and covers the quarter ended March 31, 2026.
• The Form 8‑K cites Item 2.02 (Results of Operations and Financial Condition); the press release is included as Exhibit 99.1.
• The filing includes the Inline XBRL cover page (Exhibit 104).
• The company notes, per Form instructions, that the information and Exhibit 99.1 are not to be deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters
This filing is the company’s formal disclosure of its quarterly earnings and financial condition for Q1 2026. Retail investors should read the attached press release for details on revenue, earnings, cash position, and any operational updates, since the 8‑K itself references that press release as the full source of the quarterly results. The filing’s technical note about Section 18 simply clarifies legal treatment of the release and does not affect the substance of the reported results.